CenExel is a leading clinical trial site network focused on complex therapeutic areas. The transaction allows the company to advance its mission of providing state-of-the-art clinical research centers to the nation’s leading pharmaceutical companies. Webster Equity Partners will retain a minority stake in the company after the transaction closes.

Reed Smith worked with Webster Equity Partners as health care counsel on its initial investment in CenExel, and was honored to work with the company as it has expanded its services. The Reed Smith team that served as health care regulatory counsel on the sale transaction was led by partner Nicole Aiken-Shaban, and included partner Carol Loepere, counsel Sarah Thompson Schick, and associates Taber Reuter and Seb Dugmeoglu.

More information on the transaction can be found on the Businesswire news release.